Precigen Celebrates Third RRP Awareness Day After FDA Approval of First RRP Immunotherapy
PGEN•Precigen and the Recurrent Respiratory Papillomatosis Foundation co-hosted the third International RRP Awareness Day, spotlighting patient, caregiver and provider experiences. The event follows the FDA’s August 2025 approval of Precigen’s HPV-specific immunotherapy, the first adult RRP treatment, for an estimated 27,000 US and 170,000 worldwide adult patients.
1. Third International RRP Awareness Day
On June 11, Precigen and the Recurrent Respiratory Papillomatosis Foundation highlighted patient, caregiver and provider experiences across digital and virtual platforms to deepen public understanding of RRP.
2. Disease Burden and Patient Population
RRP is a rare chronic disease caused by persistent HPV 6 or 11 infection, affecting an estimated 27,000 adults in the US and more than 170,000 adults worldwide with recurrent respiratory tract tumors.
3. First FDA-Approved RRP Immunotherapy
In August 2025 the FDA approved Precigen’s HPV-specific immunotherapy as the first and only treatment for adults with RRP, marking a historic milestone in a century-long search for approved therapies.
4. Patient Voices and Community Engagement
The campaign hub features patient quotes, videos and reflections to amplify lived experiences, support families and encourage broader awareness and research investment in RRP.
